Tag Archives: BIO CEO & Investor Conference

Nasdaq Social Bell: Twitter Strategies For Biotechs

Nasdaq Social Bell

Last week at the BIO CEO & Investor Conference in New York City, I had the pleasure of speaking with John Machiz and Brad Smith from Nasdaq at their headquarters in Times Square to discuss the social media activity that happened onsite during the event, what made the discussion of the event online so robust, and what biotech companies can do to increase their visibility on Twitter. View the video below, and get a recap of the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Deal Structures: More Options for Companies

CEO2013_115x75_Thumbnail copy

By most measures, 2014 was a great year for the biotechnology industry. Venture capital deal values, , licensing values and volume were all up, as were big pharma M&A deals and asset swaps. What do these trends mean for dealmakers in 2015? Answering that question was the task of a panel at the 2015 BIO CEO & Investor Conference, Emerging Trends in Deal Structures. Moderated by Fenwick and West’s Effie Toshav, the panel included: Bruce Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Fireside Chats with Five CEOs Featured at Day Two of the BIO CEO & Investor Conference

DSC_9222

Fireside Chat with John F. Milligan, PhD, President & COO, Gilead Sciences The first fireside chat of the BIO CEO and Investor Conference featured John F. Milligan, Ph.D. President & COO of Gilead Sciences.  In a session moderated by Barclays analyst Geoff Meacham, Dr. Milligan was optimistic that sales of Gilead’s Hepatitis C treatments would see expanded sales volumes as more providers become comfortable with the regimens and treating HCV patients, according to Milligan. He Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Session Recap: “Trust Your Gut” – Therapeutic Opportunities from the Microbiome

Kaylee_dna_115x76

Tuesday at the BIO CEO & Investor Conference kicked off with a Therapeutic Workshop titled, “Trust Your Gut” – Therapeutic Opportunities from the Microbiome. The panel was moderated by Mark Breidenbach, PhD, Equity Research Group, H.C. Wainwright & Co. The panelists were: Martin J. Blaser, MD, Muriel and George Singer Professor of Medicine, Professor of Microbiology, Director, Human Microbiome Program, New York University Langone Medical Center Karim Dabbagh, PhD, Chief Scientific Officer, Second Genome Michael Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Ten Years of Therapeutic Venture Capital

vc-blog

What therapeutic areas have received the most funding in private drug companies over the last decade? How much of this has been for new drugs vs drug delivery? How much into biologics vs small molecules? This week, we released a first-of-its-kind, comprehensive report on venture capital trends covering 2004-2013. To investigate investor trends in specific therapeutic areas and level of innovation, we analyzed data from four venture capital databases to create the broadest, most comprehensive Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,